Bacterial Immunotherapy is Highly Effective in Reducing Recurrent Upper Respiratory Tract Infections in Children: a Prospective Observational Study

Overview

Journal Eur Arch Otorhinolaryngol

Specialty Otorhinolaryngology

Date 2023 May 30

PMID 37254001

Authors

Laura Rebolledo

Carmen Rodriguez-Vigil

Luis Carmen

Eva Llorente

Maria Guallar

Jesus Villoria

Eugenio Vicente

Affiliations

Soon will be listed here.

Abstract

Purpose: Whilst immunotherapy is an appealing option as it could reduce the burden of recurrent pediatric respiratory tract infections (RTI), there is limited evidence on its effectiveness and more research was requested in order to better understand this therapeutic modality.

Methods: We performed a prospective cohort study involving 57 subjects to assess the safety and effectiveness a 3-month regimen of either typified or patient-specific bacterial lysates could have in reducing the number of RTIs in children aged 0 to 11 years with histories of recurrent episodes.

Results: After a 6-month follow-up, the number of RTIs and school absenteeism dropped sharply and significantly, from an adjusted mean (standard error) of 0.6 (0.04) episodes/month to 0.1 (0.03) episodes/month (74.7% reduction, P < 0.001), and from an adjusted mean score of 4.6 (1.06) points to 0.0 (0.01) points over 10 (99.5% reduction, P < 0.001), respectively. There was also a significant decrease in the severity of symptoms. No adverse reactions were observed.

Conclusion: The use of the study product is associated with a decreased risk of recurrent RTIs in children, with a very favorable safety profile that warrants further investigation in randomized clinical trials.

Citing Articles

Digital Health Technologies in Pediatric Infectious Disease and the Perspective of Patients and Healthcare Professionals: A Review.

Saji A, Komel A, Khan M, Niraula S, Naeem B, Ahsan A Health Sci Rep. 2025; 8(3):e70514.

PMID: 40041773 PMC: 11872690. DOI: 10.1002/hsr2.70514.

Long-term sublingual bacterial immunotherapy prevents ear, nose and throat infections: A real-life study.

Aarestrup P, Aarestrup M, Jv Aarestrup B, Cheloni E, Aarestrup F SAGE Open Med. 2025; 13:20503121241309514.

PMID: 39867665 PMC: 11760123. DOI: 10.1177/20503121241309514.

Is There a Role for Immunostimulant Bacterial Lysates in the Management of Respiratory Tract Infection?.

Di Gioacchino M, Santilli F, Pession A Biomolecules. 2024; 14(10).

PMID: 39456182 PMC: 11505618. DOI: 10.3390/biom14101249.

Advances in Bacterial Lysate Immunotherapy for Infectious Diseases and Cancer.

Rahman M, Grice I, Ulett G, Wei M J Immunol Res. 2024; 2024:4312908.

PMID: 38962577 PMC: 11221958. DOI: 10.1155/2024/4312908.

Insights into the role of the respiratory tract microbiome in defense against bacterial pneumonia.

Drigot Z, Clark S Curr Opin Microbiol. 2024; 77:102428.

PMID: 38277901 PMC: 10922932. DOI: 10.1016/j.mib.2024.102428.

References

Feleszko W, Marengo R, Sousa Vieira A, Ratajczak K, Mayorga Butron J . Immunity-targeted approaches to the management of chronic and recurrent upper respiratory tract disorders in children. Clin Otolaryngol. 2019; 44(4):502-510. PMC: 6850198. DOI: 10.1111/coa.13335. View

Feleszko W, Ruszczynski M, Zalewski B . Non-specific immune stimulation in respiratory tract infections. Separating the wheat from the chaff. Paediatr Respir Rev. 2013; 15(2):200-6. DOI: 10.1016/j.prrv.2013.10.006. View

van Houten C, Cohen A, Engelhard D, Hays J, Karlsson R, Moore E . Antibiotic misuse in respiratory tract infections in children and adults-a prospective, multicentre study (TAILORED Treatment). Eur J Clin Microbiol Infect Dis. 2019; 38(3):505-514. PMC: 6394715. DOI: 10.1007/s10096-018-03454-2. View

Fendrick A, Monto A, Nightengale B, Sarnes M . The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med. 2003; 163(4):487-94. DOI: 10.1001/archinte.163.4.487. View

Cazzola M, Anapurapu S, Page C . Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: a meta-analysis. Pulm Pharmacol Ther. 2011; 25(1):62-8. DOI: 10.1016/j.pupt.2011.11.002. View

Kearney S, Dziekiewicz M, Feleszko W . Immunoregulatory and immunostimulatory responses of bacterial lysates in respiratory infections and asthma. Ann Allergy Asthma Immunol. 2015; 114(5):364-9. DOI: 10.1016/j.anai.2015.02.008. View

Holmgren J, Czerkinsky C . Mucosal immunity and vaccines. Nat Med. 2005; 11(4 Suppl):S45-53. DOI: 10.1038/nm1213. View

Levy O . Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol. 2007; 7(5):379-90. DOI: 10.1038/nri2075. View

Levy O, Zarember K, Roy R, Cywes C, Godowski P, Wessels M . Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848. J Immunol. 2004; 173(7):4627-34. DOI: 10.4049/jimmunol.173.7.4627. View

10.

Bach J . The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med. 2002; 347(12):911-20. DOI: 10.1056/NEJMra020100. View

11.

Scudellari M . News Feature: Cleaning up the hygiene hypothesis. Proc Natl Acad Sci U S A. 2017; 114(7):1433-1436. PMC: 5320962. DOI: 10.1073/pnas.1700688114. View

12.

Pregliasco F, Terracciano L, Marcassa S, Zava D, Anselmi G . Rationale for the clinical use of a ribosome-component immune modulator. Allergy Asthma Proc. 2009; 30 Suppl 1:S5-12. DOI: 10.2500/aap.2009.30.3249. View

13.

Bellanti J, Settipane R . Bacterial vaccines and the innate immune system: a journey of rediscovery for the allergist-immunologist and all health care providers. Allergy Asthma Proc. 2009; 30 Suppl 1:S3-4. DOI: 10.2500/aap.2009.30.3251. View

14.

Alecsandru D, Valor L, Sanchez-Ramon S, Gil J, Carbone J, Navarro J . Sublingual therapeutic immunization with a polyvalent bacterial preparation in patients with recurrent respiratory infections: immunomodulatory effect on antigen-specific memory CD4+ T cells and impact on clinical outcome. Clin Exp Immunol. 2011; 164(1):100–7. PMC: 3074222. DOI: 10.1111/j.1365-2249.2011.04320.x. View

15.

Schaad U . OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review. World J Pediatr. 2010; 6(1):5-12. DOI: 10.1007/s12519-010-0001-x. View

16.

Steurer-Stey C, Lagler L, Straub D, Steurer J, Bachmann L . Oral purified bacterial extracts in acute respiratory tract infections in childhood: a systematic quantitative review. Eur J Pediatr. 2006; 166(4):365-76. DOI: 10.1007/s00431-006-0248-3. View

17.

Yin J, Xu B, Zeng X, Shen K . Broncho-Vaxom in pediatric recurrent respiratory tract infections: A systematic review and meta-analysis. Int Immunopharmacol. 2017; 54:198-209. DOI: 10.1016/j.intimp.2017.10.032. View

18.

Esposito S, Soto-Martinez M, Feleszko W, Jones M, Shen K, Schaad U . Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence. Curr Opin Allergy Clin Immunol. 2018; 18(3):198-209. PMC: 6037280. DOI: 10.1097/ACI.0000000000000433. View

19.

Kleiner G, Marcuzzi A, Zanin V, Monasta L, Zauli G . Cytokine levels in the serum of healthy subjects. Mediators Inflamm. 2013; 2013:434010. PMC: 3606775. DOI: 10.1155/2013/434010. View

20.

Said E, Al-Reesi I, Al-Shizawi N, Jaju S, Al-Balushi M, Koh C . Defining IL-6 levels in healthy individuals: A meta-analysis. J Med Virol. 2020; 93(6):3915-3924. DOI: 10.1002/jmv.26654. View